CD32A+CD32B+CD32C抗体;CD32A+CD32B+CD32C Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of CD32A + CD32B + CD32C expression in U937 cell lysate.    

  
  

CD32 (FcγRII), a family of low-affinity receptors for the Fc region of IgG, plays critical roles in immune regulation. CD32 exists in three major isoforms—CD32A (FcγRIIA), CD32B (FcγRIIB), and CD32C (FcγRIIC)—encoded by distinct genes (FcγRIIA, FcγRIIB, FcγRIIC) or splice variants. CD32A is an activating receptor expressed primarily on myeloid cells (e.g., monocytes, macrophages, neutrophils) and platelets. It contains an immunoreceptor tyrosine-based activation motif (ITAM) that triggers phagocytosis, cytokine release, and antibody-dependent cellular cytotoxicity (ADCC). CD32B, in contrast, is an inhibitory receptor widely expressed on B cells, dendritic cells, and myeloid cells. It carries an immunoreceptor tyrosine-based inhibitory motif (ITIM) that dampens B-cell activation and immune complex-mediated inflammation. CD32C, a less studied isoform, shares structural similarities with CD32A but is expressed in limited tissues, including activated T cells and epithelial cells, and may participate in immune modulation.

Antibodies targeting CD32 isoforms have therapeutic and research applications. Anti-CD32A/B/C antibodies are used to study immune cell signaling, autoimmune diseases (e.g., lupus), and infectious responses. In cancer, CD32B blockade enhances antitumor immunity by countering immunosuppression, while CD32A engagement may amplify effector cell activity. However, functional overlap and tissue-specific expression complicate their selective targeting, driving ongoing research into isoform-specific antibodies for precision immunotherapy.